Skip to content

Study · Not a test of the peptide alone · 1991

3 results

[Immunocorrection in the combined treatment of patients with osteomyelitis developing following combined injuries to the maxillofacial and craniocerebral areas].

Grigoriants LA, Zuev VP, Rakhmetov BR, Eremeev VV, Abramova ZP, Litvinova LL

Stomatologiia1 Sept 1991

PMID1798997 (opens in a new tab)PepBankPUB-01798997
Publisher pageAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Thymogen (oglufanide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymogen (oglufanide).

  1. 01HumanNot a test of Thymogen (oglufanide) aloneNon-randomized trialEfficacy outcome

    In post-traumatic osteomyelitis patients, combined therapy with thymogen contributed to normalization of immunologic reactivity.

    In plain wordsIn post-traumatic osteomyelitis patients, combined therapy with thymogen contributed to normalization of immune reactivity.

    Peptide
    Thymogen (oglufanide)
    Outcome
    Not applicableImmunologic reactivity
    Study

    n = 21

    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Thymogen therapy was conducive to normalization of the immunologic and nonspecific reactivity and enhanced the treatment efficacy on the whole.
    1 context sentence
    Summary · context
    Twenty-one of the forty-two patients with osteomyelitis developing after a combined maxillofacial and craniocerebral injury were administered thymogen, an immunocorrective drug, as a component of combined therapy; immunologic indications for the prescription of such an agent were present in all these patients.

    In this study, Thymogen (oglufanide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymogen (oglufanide).

  2. 02HumanNot a test of Thymogen (oglufanide) aloneNon-randomized trialEfficacy outcome

    In post-traumatic osteomyelitis patients, combined therapy with thymogen contributed to normalization of nonspecific reactivity.

    In plain wordsIn post-traumatic osteomyelitis patients, combined therapy with thymogen contributed to normalization of nonspecific reactivity.

    Peptide
    Thymogen (oglufanide)
    Outcome
    Not applicableNonspecific reactivity
    Study

    n = 21

    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Thymogen therapy was conducive to normalization of the immunologic and nonspecific reactivity and enhanced the treatment efficacy on the whole.
    1 context sentence
    Summary · context
    Twenty-one of the forty-two patients with osteomyelitis developing after a combined maxillofacial and craniocerebral injury were administered thymogen, an immunocorrective drug, as a component of combined therapy; immunologic indications for the prescription of such an agent were present in all these patients.

    In this study, Thymogen (oglufanide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymogen (oglufanide).

  3. 03HumanNot a test of Thymogen (oglufanide) aloneNon-randomized trialEfficacy outcome

    In post-traumatic osteomyelitis patients, combined therapy with thymogen enhanced overall treatment efficacy.

    In plain wordsIn post-traumatic osteomyelitis patients, combined therapy with thymogen improved overall treatment results.

    Peptide
    Thymogen (oglufanide)
    Outcome
    IncreaseOverall treatment efficacy
    Study

    n = 21

    Outcome group
    Infection and antimicrobial activity · Musculoskeletal

    Source sentences

    Summary
    Thymogen therapy was conducive to normalization of the immunologic and nonspecific reactivity and enhanced the treatment efficacy on the whole.
    1 context sentence
    Summary · context
    Twenty-one of the forty-two patients with osteomyelitis developing after a combined maxillofacial and craniocerebral injury were administered thymogen, an immunocorrective drug, as a component of combined therapy; immunologic indications for the prescription of such an agent were present in all these patients.

    In this study, Thymogen (oglufanide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymogen (oglufanide).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.